BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
FRA:BSX - Deutsche Boerse Ag - US1011371077 - Common Stock - Currency: EUR
We assign a fundamental rating of 5 out of 10 to BSX. BSX was compared to 53 industry peers in the Health Care Equipment & Supplies industry. While BSX has a great profitability rating, there are some minor concerns on its financial health. BSX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year BSX was profitable.
In the past year BSX had a positive cash flow from operations.
Of the past 5 years BSX 4 years were profitable.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 4.71%, BSX is doing good in the industry, outperforming 71.70% of the companies in the same industry.
The Return On Equity of BSX (8.52%) is better than 67.92% of its industry peers.
BSX has a Return On Invested Capital of 7.43%. This is in the better half of the industry: BSX outperforms 77.36% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is in line with the industry average of 8.25%.
The last Return On Invested Capital (7.43%) for BSX is above the 3 year average (6.54%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.52% | ||
| ROIC | 7.43% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
BSX has a better Profit Margin (11.07%) than 81.13% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 18.18%, BSX belongs to the best of the industry, outperforming 86.79% of the companies in the same industry.
BSX's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 68.64%, BSX is in the better half of the industry, outperforming 75.47% of the companies in the same industry.
BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.18% | ||
| PM (TTM) | 11.07% | ||
| GM | 68.64% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
Compared to 1 year ago, BSX has a worse debt to assets ratio.
2.2 Solvency
BSX has an Altman-Z score of 6.06. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
BSX's Altman-Z score of 6.06 is amongst the best of the industry. BSX outperforms 94.34% of its industry peers.
BSX has a debt to FCF ratio of 4.06. This is a neutral value as BSX would need 4.06 years to pay back of all of its debts.
BSX's Debt to FCF ratio of 4.06 is fine compared to the rest of the industry. BSX outperforms 71.70% of its industry peers.
A Debt/Equity ratio of 0.41 indicates that BSX is not too dependend on debt financing.
BSX has a Debt to Equity ratio of 0.41. This is comparable to the rest of the industry: BSX outperforms 50.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | 4.06 | ||
| Altman-Z | 6.06 |
ROIC/WACC0.88
WACC8.49%
2.3 Liquidity
BSX has a Current Ratio of 1.08. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
BSX has a worse Current ratio (1.08) than 66.04% of its industry peers.
A Quick Ratio of 0.64 indicates that BSX may have some problems paying its short term obligations.
The Quick ratio of BSX (0.64) is worse than 73.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.08 | ||
| Quick Ratio | 0.64 |
3. Growth
3.1 Past
BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.17%, which is quite impressive.
Measured over the past years, BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.35% in the last year.
Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 9.30% on average per year.
EPS 1Y (TTM)26.17%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%33.93%
Revenue 1Y (TTM)19.35%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.93%
3.2 Future
Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.15% on average per year.
BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.22% yearly.
EPS Next Y15.1%
EPS Next 2Y14.53%
EPS Next 3Y13.94%
EPS Next 5Y12.15%
Revenue Next Year15.63%
Revenue Next 2Y12.95%
Revenue Next 3Y11.93%
Revenue Next 5Y10.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 39.08 indicates a quite expensive valuation of BSX.
BSX's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 24.12, BSX is valued quite expensively.
BSX is valuated quite expensively with a Price/Forward Earnings ratio of 32.09.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of BSX to the average of the S&P500 Index (20.42), we can say BSX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.08 | ||
| Fwd PE | 32.09 |
4.2 Price Multiples
BSX's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSX is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.1 | ||
| EV/EBITDA | 38.31 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
BSX's earnings are expected to grow with 13.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.59
PEG (5Y)4.09
EPS Next 2Y14.53%
EPS Next 3Y13.94%
5. Dividend
5.1 Amount
No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (5/8/2025, 7:00:00 PM)
93
+0.8 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.1%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap137.55B
Analysts83.68
Price Target103.37 (11.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.94%
Min EPS beat(2)5.6%
Max EPS beat(2)6.28%
EPS beat(4)4
Avg EPS beat(4)6.44%
Min EPS beat(4)5.6%
Max EPS beat(4)8.11%
EPS beat(8)8
Avg EPS beat(8)6.21%
EPS beat(12)11
Avg EPS beat(12)4.28%
EPS beat(16)15
Avg EPS beat(16)5.09%
Revenue beat(2)2
Avg Revenue beat(2)2.6%
Min Revenue beat(2)2.04%
Max Revenue beat(2)3.16%
Revenue beat(4)4
Avg Revenue beat(4)2.58%
Min Revenue beat(4)1.53%
Max Revenue beat(4)3.6%
Revenue beat(8)8
Avg Revenue beat(8)2.69%
Revenue beat(12)10
Avg Revenue beat(12)1.82%
Revenue beat(16)12
Avg Revenue beat(16)1.68%
PT rev (1m)-5.2%
PT rev (3m)3.77%
EPS NQ rev (1m)0.06%
EPS NQ rev (3m)4.24%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.94%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)2.71%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)2.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.08 | ||
| Fwd PE | 32.09 | ||
| P/S | 9.33 | ||
| P/FCF | 59.1 | ||
| P/OCF | 45.5 | ||
| P/B | 7.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | 38.31 |
EPS(TTM)2.38
EY2.56%
EPS(NY)2.9
Fwd EY3.12%
FCF(TTM)1.57
FCFY1.69%
OCF(TTM)2.04
OCFY2.2%
SpS9.97
BVpS12.96
TBVpS-1.19
PEG (NY)2.59
PEG (5Y)4.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.52% | ||
| ROCE | 9.23% | ||
| ROIC | 7.43% | ||
| ROICexc | 7.53% | ||
| ROICexgc | 27.84% | ||
| OM | 18.18% | ||
| PM (TTM) | 11.07% | ||
| GM | 68.64% | ||
| FCFM | 15.79% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexcg growth 3Y8.56%
ROICexcg growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | 4.06 | ||
| Debt/EBITDA | 2.08 | ||
| Cap/Depr | 62.25% | ||
| Cap/Sales | 4.72% | ||
| Interest Coverage | 12.18 | ||
| Cash Conversion | 79.6% | ||
| Profit Quality | 142.61% | ||
| Current Ratio | 1.08 | ||
| Quick Ratio | 0.64 | ||
| Altman-Z | 6.06 |
F-Score6
WACC8.49%
ROIC/WACC0.88
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.17%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%33.93%
EPS Next Y15.1%
EPS Next 2Y14.53%
EPS Next 3Y13.94%
EPS Next 5Y12.15%
Revenue 1Y (TTM)19.35%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.93%
Revenue Next Year15.63%
Revenue Next 2Y12.95%
Revenue Next 3Y11.93%
Revenue Next 5Y10.22%
EBIT growth 1Y25.41%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year30.91%
EBIT Next 3Y18.53%
EBIT Next 5Y14.08%
FCF growth 1Y47.54%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y37.2%
OCF growth 3Y22.44%
OCF growth 5Y13.34%